Accurate Diagnosis for Brain Diseases

  • Brain diseases are difficult to diagnose
    • Brain Scans: 36 million per year (US)
    • Spinal Taps: 363,000 per year (US)
  • Treatable brain diseases like Multiple Sclerosis (MS) and Parkinson’s Disease (PD) are misdiagnosed 18 to 30% of the time
  • 2 million Americans suffer from MS or PD

The Challenge

Invasive and Inaccurate

Screening protocols for neurologic diseases – including Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease (PD), and Alzheimer’s Disease (AD) – currently rely on imprecise and invasive diagnostic procedures.
 
Some of these brain disease are misdiagnosed up to a third of the time, leading to incorrect treatment protocols and the use of wrong medications.

Our Solution

RNA Biomarkers

FBB Biomed’s newly discovered RNA biomarkers increase diagnostic accuracy at the time of screening by providing a molecular diagnostic for MS, PD, and AD.
 
FBB Biomed’s pre-clinical research has demonstrated significant potential for earlier, more accurate diagnosis of these diseases.

Our Product

NGS-based Blood Test

FBB Biomed’s proprietary reagent and bioinformatics software power our blood test based on RNA biomarkers. Our test provides neurologists with a liquid biopsy for the diagnosis of Multiple Sclerosis, Parkinson’s Disease, and Alzheimer’s Disease.

Our test runs on standard laboratory sequencing equipment and protocols. No new hardware or processes required.

Actionable Clinical Utility

Use Cases

Early Diagnosis

Is this patient suffering from neurodegeneration?

Differential Diagnosis

Which neurologic disease does this patient have?

Patient Monitoring

How effective has the prescribed therapy been so far?

From the Scientific Community

What Others Say About Us